- Home
- TCBX vs RIGL Comparison
TCBX vs RIGL Comparison
Compare TCBX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBX | RIGL |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.8M | 537.6M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TCBX | RIGL |
|---|---|---|
| Price | $40.45 | $42.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $41.67 | ★ $43.20 |
| AVG Volume (30 Days) | 70.4K | ★ 562.5K |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.90 | ★ 2698.26 |
| EPS | 3.56 | ★ 6.20 |
| Revenue | $192,224,000.00 | ★ $282,076,000.00 |
| Revenue This Year | $24.66 | $65.53 |
| Revenue Next Year | $17.56 | $0.22 |
| P/E Ratio | $11.34 | ★ $6.71 |
| Revenue Growth | 20.96 | ★ 79.13 |
| 52 Week Low | $25.17 | $14.63 |
| 52 Week High | $41.70 | $52.24 |
Technical Indicators
Market Signals| Indicator | TCBX | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 52.75 |
| Support Level | $40.11 | $40.52 |
| Resistance Level | $41.70 | $43.58 |
| Average True Range (ATR) | 0.99 | 2.55 |
| MACD | 0.14 | -0.70 |
| Stochastic Oscillator | 62.30 | 35.52 |
Price Performance
Historical ComparisonAbout TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.